Lyra Therapeutics Inc (LYRA) Stock Price, Quote & News

Company Profile

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhi...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 393 4600

Website: lyratherapeutics.com

Address:

480 Arsenal Way, Watertown, United States

TwongStocks Apr. 17 at 12:09 PM

$LYRA Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC https://investors.lyratherapeutics.com/news-releases/news-release-details/lyra-therapeutics-inc-announces-intention-voluntarily-file-form It is already trading OTC, so the Form 25 filing is a formality. However, after the Form 25 is effective, they intend to file a Form 15. This will terminate its registration with the SEC. The company will no longer be subject to SEC reporting requirements after the Form 15 filing. They won't be required to make any more 10-K, 10-Q, or 8-K filings after the Form 15 is effective.

1 · Reply

focafoca99 Apr. 10 at 6:09 PM

$LYRA agreed to terminate part of its Watertown lease early, forfeiting its security deposit and paying $1.X million to exit the space sooner.

0 · Reply

revuelto Apr. 7 at 9:28 PM

$LYRA Maria still holds 1.1M shares and Jason 519K…clearly they don’t view their stakes as worthless...at this point just acquire it for $10 a share and put an end to the chicanery..and don’t take this as investment advice..this could absolutely go to zero, so any position should be treated accordingly...that said, I find it difficult to believe the enterprise is truly worthless🤷‍♂️

1 · Reply

Fishintheocean Apr. 6 at 10:03 PM

$LYRA anyone still holding? Holding 563 shares @ .3501 still… can’t hurt

0 · Reply

ProfProfit Mar. 20 at 8:12 PM

$LYRA I sold this off at $30 last June. What the fuck happened to it???

0 · Reply

TwongStocks Mar. 17 at 12:06 PM

$LYRA Begins trading on pink sheets today https://www.otcmarkets.com/stock/LYRA/overview

0 · Reply

focafoca99 Mar. 17 at 6:29 AM

$LYRA got the delisting/non-compliance filing on record...

0 · Reply

DARKP00L Mar. 17 at 12:41 AM

$LYRA 17:11 on Mar. 16 2026 Lyra Therapeutics Withdraws Appeal Of Nasdaq Delisting Determination; Trading In Co's Common Stock To Be Suspended At Open On March 17, 2026 #tradeideas

0 · Reply

Raymondsuper Mar. 16 at 10:51 PM

$LYRA very unfortunate but I bought it 30+cents for lottery play even it goes to zero few hundred dollars is mean nothing to me good luck all

0 · Reply

TwongStocks Mar. 16 at 10:44 PM

$LYRA FINRA confirms it will begin trading OTC tomorrow. Same symbol. https://otce.finra.org/otce/dailyList?viewType=Additions

0 · Reply

Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC

Jan 12, 2026, 7:00 AM EST - 3 months ago

Lyra Therapeutics Provides Corporate Update

Nov 12, 2025, 4:01 PM EST - 5 months ago

Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 6, 2025, 7:00 AM EDT - 7 months ago

Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study

Aug 12, 2025, 4:01 PM EDT - 9 months ago

Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 27, 2025, 8:00 AM EDT - 10 months ago

Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Jun 2, 2025, 8:29 AM EDT - 11 months ago

Why Is Lyra Therapeutics Stock Surging Over 400% On Monday?

Jun 2, 2025, 7:00 AM EDT - 11 months ago

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)

May 7, 2025, 7:00 AM EDT - 1 year ago

Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025

May 6, 2025, 4:01 PM EDT - 1 year ago

Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mar 13, 2025, 4:01 PM EDT - 1 year ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Nov 12, 2024, 4:01 PM EST - 1 year ago

Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Sep 27, 2024, 7:00 AM EDT - 1 year ago

Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

May 21, 2024, 9:14 AM EDT - 2 years ago

Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital

May 6, 2024, 7:59 AM EDT - 2 years ago

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

Apr 30, 2024, 4:04 PM EDT - 2 years ago

Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 26, 2024, 4:51 PM EDT - 2 years ago

Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 21, 2024, 4:01 PM EDT - 2 years ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 1, 2024, 4:01 PM EST - 2 years ago

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 7, 2023, 4:01 PM EST - 2 years ago

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 7:00 AM EST - 2 years ago

Lyra Therapeutics to Participate in Upcoming Investor Conferences

Oct 16, 2023, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer

Sep 12, 2023, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

Aug 29, 2023, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 13, 2023, 7:30 AM EDT - 3 years ago

Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference

Jun 2, 2023, 7:30 AM EDT - 3 years ago

Lyra Therapeutics to Present at Jefferies Healthcare Conference

Jun 1, 2023, 7:29 AM EDT - 3 years ago

Lyra Therapeutics Announces Closing of $50.0 Million Private Placement

May 26, 2023, 7:57 AM EDT - 3 years ago

Lyra Therapeutics Announces $50.0 Million Private Placement

May 12, 2023, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023, 4:01 PM EDT - 3 years ago

Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

Apr 25, 2023, 7:59 AM EDT - 3 years ago

Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis

Mar 29, 2023, 4:06 PM EDT - 3 years ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Feb 27, 2023, 7:59 AM EST - 3 years ago

Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer

Feb 6, 2023, 7:56 AM EST - 3 years ago

Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

Nov 8, 2022, 4:01 PM EST - 3 years ago

Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Sep 13, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study

Sep 10, 2022, 8:00 AM EDT - 3 years ago

LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting

Sep 8, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients

Sep 6, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022

Aug 29, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting

Aug 9, 2022, 7:00 AM EDT - 4 years ago

Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Jul 5, 2022, 7:00 AM EDT - 4 years ago

Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022

Jul 5, 2022, 7:00 AM EDT - 4 years ago

Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical Officer

May 26, 2022, 7:00 AM EDT - 4 years ago

Lyra Therapeutics to Present at Upcoming Investor Conferences

May 10, 2022, 7:00 AM EDT - 4 years ago

Lyra Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Apr 29, 2022, 9:07 AM EDT - 4 years ago

Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022

Apr 25, 2022, 7:00 AM EDT - 4 years ago

Lyra Therapeutics Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

TwongStocks Apr. 17 at 12:09 PM

1 · Reply

focafoca99 Apr. 10 at 6:09 PM

$LYRA agreed to terminate part of its Watertown lease early, forfeiting its security deposit and paying $1.X million to exit the space sooner.

0 · Reply

revuelto Apr. 7 at 9:28 PM

1 · Reply

Fishintheocean Apr. 6 at 10:03 PM

$LYRA anyone still holding? Holding 563 shares @ .3501 still… can’t hurt

0 · Reply

ProfProfit Mar. 20 at 8:12 PM

$LYRA I sold this off at $30 last June. What the fuck happened to it???

0 · Reply

TwongStocks Mar. 17 at 12:06 PM

$LYRA Begins trading on pink sheets today https://www.otcmarkets.com/stock/LYRA/overview

0 · Reply

focafoca99 Mar. 17 at 6:29 AM

$LYRA got the delisting/non-compliance filing on record...

0 · Reply

DARKP00L Mar. 17 at 12:41 AM

$LYRA 17:11 on Mar. 16 2026 Lyra Therapeutics Withdraws Appeal Of Nasdaq Delisting Determination; Trading In Co's Common Stock To Be Suspended At Open On March 17, 2026 #tradeideas

0 · Reply

Raymondsuper Mar. 16 at 10:51 PM

$LYRA very unfortunate but I bought it 30+cents for lottery play even it goes to zero few hundred dollars is mean nothing to me good luck all

0 · Reply

TwongStocks Mar. 16 at 10:44 PM

$LYRA FINRA confirms it will begin trading OTC tomorrow. Same symbol. https://otce.finra.org/otce/dailyList?viewType=Additions

0 · Reply

Raymondsuper Mar. 16 at 9:01 PM

$LYRA what is the news?

1 · Reply

TwongStocks Mar. 16 at 8:47 PM

$LYRA Delisted. Will be suspended from trading on NASDAQ at the open on March 17. https://www.sec.gov/ix?doc=/Archives/edgar/data/1327273/000119312526108439/d55950d8k.htm "On March 13, 2026, Lyra Therapeutics, Inc. (the “Company”) received a letter (the “Letter”) from the Nasdaq Hearings Advisor at The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has withdrawn its appeal of the delisting determination issued by Nasdaq’s Listings Qualifications Staff on February 2, 2026. The Letter further confirms that as a result of the withdrawal of the Company’s appeal, trading in the Company’s common stock will be suspended at the open of trading on Tuesday, March 17, 2026."

0 · Reply

Biotech_Pharma_Investor Mar. 16 at 6:57 PM

$LYRA De-listinf or bankruptcy? dont see any news

1 · Reply

Love_To_Learn Mar. 16 at 5:52 PM

$LYRA DUMPING ALL 0.56 OPTION CONTRACTS OFF THE BOOKS

0 · Reply

TheBlackBerrry Mar. 16 at 5:38 PM

$LYRA Will be liquidation only on webull and robhinhood tomorrow learn from what happened to $BHAT

0 · Reply

TheBlackBerrry Mar. 16 at 5:32 PM

$LYRA Appeal rejected

1 · Reply

TheBlackBerrry Mar. 16 at 5:31 PM

$LYRA Delisting today

1 · Reply

DisneyPalaceTrades Mar. 16 at 5:18 PM

$LYRA halted down>

0 · Reply

luminouslumens Mar. 15 at 6:20 PM

$ADV $EONR $TWAV $CYN $LYRA Multi-day runner scan going into Monday.

0 · Reply

ChetdaJet Mar. 6 at 5:47 AM

$LYRA is this company still in business??

0 · Reply

OfficialStocktwitsUser Mar. 3 at 3:25 PM

$LYRA RSI: 36.24, MACD: -0.2954 Vol: 0.25, MA20: 1.45, MA50: 2.23 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

StockScanners Mar. 3 at 6:40 AM

$LYRA keep watch if this holds above .99

0 · Reply

Market Cap	2.34M
Revenue (ttm)	1.53M
Net Income (ttm)	-93.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,107.19%
Debt to Equity Ratio	0.00

Volume	176,300
Avg Vol	120,622
Day's Range	N/A - N/A
Shares Out	1.78M
Stochastic %K	17%
Beta	0.00
Analysts	Hold
Price Target	$16.00